Investor's Business Daily - Investing RSS http://ift.tt/ZZsD4K Earnings over the past few quarters for Gilead Sciences (GILD) have been driven by record-breaking sales of Sovaldi, a drug that treats hepatitis C. The retail cost of a 12-week treatment is $84,000. That's led to some backlash from insurers. But in clinical trials, Sovaldi has had a 95% cure rate. That's better than any previous treatment medical science has come up with. Gilead has also reported favorable results in late-stage trials for a new
No comments:
Post a Comment